Pacer Advisors Inc. Sells 913,713 Shares of BioMarin Pharmaceutical Inc. $BMRN

Pacer Advisors Inc. cut its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 97.5% in the first quarter, Holdings Channel reports. The fund owned 23,643 shares of the biotechnology company’s stock after selling 913,713 shares during the period. Pacer Advisors Inc.’s holdings in BioMarin Pharmaceutical were worth $1,336,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Norges Bank bought a new stake in shares of BioMarin Pharmaceutical in the 4th quarter worth about $447,572,000. Vestal Point Capital LP boosted its position in BioMarin Pharmaceutical by 261.4% in the fourth quarter. Vestal Point Capital LP now owns 3,000,000 shares of the biotechnology company’s stock valued at $178,290,000 after buying an additional 2,170,000 shares in the last quarter. Viking Global Investors LP boosted its position in BioMarin Pharmaceutical by 13.8% in the second quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock valued at $675,505,000 after buying an additional 1,488,552 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in BioMarin Pharmaceutical by 48.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,321,754 shares of the biotechnology company’s stock worth $197,405,000 after buying an additional 1,076,568 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its holdings in shares of BioMarin Pharmaceutical by 3,494.9% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 957,011 shares of the biotechnology company’s stock worth $56,875,000 after buying an additional 930,390 shares in the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

Trending Headlines about BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Q2 results exceeded expectations. BioMarin reported adjusted earnings of $1.20 per share versus the $0.95–$0.96 analyst consensus, while revenue rose 20% year over year to approximately $990 million, ahead of estimates near $932 million. BioMarin Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its 2026 outlook. Full-year adjusted EPS guidance increased to $4.90-$5.10 from a prior level below that range and above the roughly $4.80 consensus. Revenue guidance was set around $3.9 billion. Stronger-than-expected VOXZOGO sales and continued momentum in key therapies supported the revision. BioMarin Reports Second Quarter 2026 Results
• Positive Sentiment: Amicus additions could improve long-term growth. BioMarin said the addition of GALAFOLD and POMBILITI plus OPFOLDA, along with cost synergies, should accelerate revenue growth, earnings accretion, operating-margin expansion and cash flow through the mid-2030s. BioMarin Lifts 2026 Outlook
• Positive Sentiment: Morgan Stanley raised its price target to $124 from $119 and maintained an Overweight rating, signaling substantial potential upside in its valuation view.
• Neutral Sentiment: HC Wainwright increased its target to $60 from $50 but retained a Neutral rating, indicating more cautious expectations than Morgan Stanley.
• Negative Sentiment: BioMarin discontinued a $270 million rare-disease asset after the treatment missed its Phase 3 endpoint. The setback removes a potential growth opportunity and highlights clinical-development risk. BioMarin Axes Rare-Disease Asset

BioMarin Pharmaceutical Stock Performance

BioMarin Pharmaceutical stock opened at $63.81 on Friday. The company has a current ratio of 5.81, a quick ratio of 4.20 and a debt-to-equity ratio of 0.23. BioMarin Pharmaceutical Inc. has a 1 year low of $49.26 and a 1 year high of $66.28. The company has a market cap of $12.33 billion, a PE ratio of 172.46, a PEG ratio of 0.49 and a beta of 0.24. The company’s 50-day moving average is $58.19 and its two-hundred day moving average is $57.06.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping the consensus estimate of $0.95 by $0.25. The company had revenue of $989.71 million during the quarter, compared to analysts’ expectations of $932.03 million. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.36%. BioMarin Pharmaceutical’s revenue was up 20.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.44 EPS. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Equities analysts anticipate that BioMarin Pharmaceutical Inc. will post 4.22 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Weiss Ratings upgraded shares of BioMarin Pharmaceutical from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, June 26th. Canaccord Genuity Group decreased their price target on BioMarin Pharmaceutical from $116.00 to $111.00 and set a “buy” rating on the stock in a research report on Friday, May 22nd. Citigroup raised their price target on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Royal Bank Of Canada cut their price objective on BioMarin Pharmaceutical from $66.00 to $62.00 and set a “sector perform” rating for the company in a research report on Tuesday, July 7th. Finally, UBS Group restated a “neutral” rating on shares of BioMarin Pharmaceutical in a report on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.86.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.